Memantine
Memantine is an FDA-approved prescription medication for moderate-to-severe Alzheimer's disease; it is an NMDA-receptor antagonist with low abuse potential, included here for context alongside the dissociatives it is chemically related to.
Overview
Memantine is a prescription medication approved by the U.S. Food and Drug Administration to treat moderate-to-severe Alzheimer's disease. It is sold as a tablet, an extended-release capsule, and an oral solution, and is often prescribed together with a different class of Alzheimer's drug (cholinesterase inhibitors such as donepezil). Memantine does not cure Alzheimer's disease; it can help moderate symptoms and slow some of the decline associated with it. It is included in this library mainly for context: memantine acts on the same NMDA-receptor system as dissociative drugs like ketamine and PCP, but it is a legitimate, well-tolerated medicine with low potential for misuse, which makes it a useful point of comparison rather than a recreational substance.
Source: MedlinePlus; FDA; NIH (StatPearls)
Chemistry & mechanism of action
Memantine is a low-affinity, uncompetitive NMDA-receptor antagonist. In Alzheimer's disease, excessive activity of the neurotransmitter glutamate at NMDA receptors is thought to contribute to ongoing nerve-cell damage. Memantine partially blocks these receptors in a way that dampens harmful overactivation while still allowing the normal signaling needed for memory and learning — a 'gentler' block than strong dissociatives produce. This is why memantine, despite sharing a receptor target with ketamine and PCP, does not produce the same intense dissociative state at therapeutic doses.
Source: NIH (StatPearls); peer-reviewed pharmacology literature
Effects
Taken as prescribed, memantine is generally well tolerated. The most common side effects include dizziness, headache, confusion, and constipation. Because it acts gradually and at controlled doses, it does not produce the euphoria or dissociative 'high' associated with recreational NMDA-blocking drugs, and it is not typically sought out for misuse. As with any medication, effects and tolerability vary between individuals, and it should be taken only as directed by a prescriber.
Source: MedlinePlus; FDA
Risks & harms
Memantine has a comparatively favorable safety profile when used as prescribed, and a low potential for abuse relative to other drugs in the dissociative family. Side effects are usually mild, but higher-than-prescribed doses or combination with other medicines can cause problems, and people with certain kidney conditions may need dose adjustments. As a prescription medication it should be taken only under medical supervision and not shared with others. If an overdose is suspected, contact Poison Control at 1-800-222-1222, or call 911 in an emergency. Anyone with questions about memantine should speak with their prescriber or pharmacist.
Source: MedlinePlus; FDA
Legal status (US)
In the United States, memantine is an FDA-approved prescription medication and is not a controlled substance under the Controlled Substances Act. It is legally available only with a prescription and is dispensed through pharmacies for the treatment of Alzheimer's disease. This is general legal information, not legal advice.
Source: FDA
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling, because penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass, most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating, move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst, but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing, long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
With dissociatives, coordination and judgment are impaired and effects can come in waves, sit or lie down somewhere safe so you don't fall, and don't drive or make decisions until it clears.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft, not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown, pending review”Identity
- PubChem CID
- 4054PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- 3,5-dimethyladamantan-1-aminePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C12H21NPubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CC12CC3CC(C1)(CC(C3)(C2)N)CPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- BUGYDGFZZOZRHP-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- namenda, 3,5-dimethyladamantan-1-amine, 1-Amino-3,5-dimethyladamantane, Memantina, 3,5-Dimethyl-1-adamantanamine, Memantinum, 1,3-Dimethyl-5-adamantanamine, nemdatine, 3,5-Dimethyl-1-aminoadamantane, 1,3-Dimethyl-5-aminoadamantane, MemantinPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- 3 DOSAGE FORMS AND STRENGTHS Memantine Hydrochloride Tablet USP, 5 mg: orange colored, oblong, biconvex, film-coated tablets debossed “IP 173” on one side and popenFDA drug label ↗ · retrieved 2026-06-18
- Shape
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Color
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Imprint
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
- Score
- Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- Unknown, pending review
Effects, risks & interactions
- Effects
- Memantine is a prescription medicine rather than a recreational drug: it is an NMDA-receptor antagonist approved to treat the symptoms of moderate-to-severe Alzheimer's disease, where it is thought to help by dampening the excessive glutamate signalling that can damage nerve cells. At therapeutic doses it is not intoxicating; unlike the dissociative anaesthetics in this class it is designed for steady daily use and does not produce their acute "dissociative" high. What people notice during treatment relates to its side-effect profile rather than to any sought-after effect.MedlinePlus Memantine + PubChem CID 4054 ↗ · retrieved 2026-06-18
- Risks
- As a medicine, memantine's risks are framed as side effects and cautions. Reported adverse effects include dizziness, headache, confusion and constipation and, less commonly, drowsiness or hallucinations. It needs careful use in people with kidney impairment, which slows how the body clears it, and in certain urinary conditions. Because it is an NMDA antagonist, any attempt to misuse it for a dissociative effect would require far more than the therapeutic amount and risks confusion, agitation and other central-nervous-system effects. As with any prescription medicine, it should be taken only as directed by a clinician.MedlinePlus Memantine + PubChem CID 4054 ↗ · retrieved 2026-06-18
- Interactions
- Memantine's approved labelling flags two interaction concerns. Drugs and conditions that make the urine more alkaline — for example carbonic-anhydrase inhibitors or sodium bicarbonate — can substantially reduce how quickly the body clears memantine, allowing it to build up and raising the chance of adverse effects. The label also states that combining memantine with other NMDA-receptor antagonists — amantadine, ketamine and dextromethorphan — has not been systematically studied and should be approached with caution.DailyMed Memantine §7 Drug Interactions ↗ · retrieved 2026-06-18
Pill catalog
Rx/OTC variants · openFDA + DailyMed (public domain) · draft, pending reviewThis drug comes in 130different versions. Make sure you’re looking at the right one, use the search above to find your exact pill by imprint, color, or shape.
Showing 24 of 130 variants
- Strength
- MEMANTINE HYDROCHLORIDE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- NDC
- 71610-011 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- NorthStar RxLLC
- NDC
- 72603-118 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 10 mg/1
- Imprint
- RDY 597
- Color
- GRAY
- Shape
- CAPSULE
- Form
- TABLET
- Labeler
- NorthStar RxLLC
- NDC
- 72603-119 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 21 mg/1
- Imprint
- R 854
- Color
- GREEN
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Rising Pharma Holdings, Inc.
- NDC
- 16571-854 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 5 mg/1
- Imprint
- 211
- Color
- ORANGE
- Shape
- CAPSULE
- Form
- TABLET, COATED
- Labeler
- Alembic Pharmaceuticals Inc.
- NDC
- 62332-075 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET, FILM COATED
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- NDC
- 71610-979 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 28 mg/1
- Imprint
- R 855
- Color
- GREEN
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Rising Pharma Holdings, Inc.
- NDC
- 16571-855 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 10 mg/1
- Imprint
- L212
- Color
- GRAY
- Shape
- CAPSULE
- Form
- TABLET, COATED
- Labeler
- Alembic Pharmaceuticals Inc.
- NDC
- 62332-076 ↗ · 2026-06-18
- Strength
- DONEPEZIL HYDROCHLORIDE 10 mg/1; MEMANTINE HYDROCHLORIDE 28 mg/1
- Imprint
- AN 1247
- Color
- yellow
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Amneal Pharmaceuticals NY LLC
- NDC
- 69238-1247 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 5 mg/1
- Imprint
- CL 27
- Color
- PINK
- Shape
- CAPSULE
- Form
- TABLET
- Labeler
- Macleods Pharmaceuticals Limited
- NDC
- 33342-297 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 7 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Major Pharmaceuticals
- NDC
- 0904-6734 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 10 mg/1
- Imprint
- CL 28
- Color
- GRAY
- Shape
- CAPSULE
- Form
- TABLET
- Labeler
- Macleods Pharmaceuticals Limited
- NDC
- 33342-298 ↗ · 2026-06-18
- Strength
- DONEPEZIL HYDROCHLORIDE 10 mg/1; MEMANTINE HYDROCHLORIDE 14 mg/1
- Imprint
- AN 1248
- Color
- green
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Amneal Pharmaceuticals NY LLC
- NDC
- 69238-1248 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 28 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Major Pharmaceuticals
- NDC
- 0904-6735 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- REMEDYREPACK INC.
- NDC
- 70518-3338 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 10 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- NCS HealthCare of KY, LLC dba Vangard Labs
- NDC
- 0615-8319 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- NDC
- 71335-2013 ↗ · 2026-06-18
- Strength
- DONEPEZIL HYDROCHLORIDE 10 mg/1; MEMANTINE HYDROCHLORIDE 14 mg/1
- Imprint
- 184
- Color
- WHITE
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Macleods Pharmaceuticals Limited
- NDC
- 33342-312 ↗ · 2026-06-18
- Strength
- DONEPEZIL HYDROCHLORIDE 10 mg/1; MEMANTINE HYDROCHLORIDE 28 mg/1
- Imprint
- 185
- Color
- ORANGE
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Macleods Pharmaceuticals Limited
- NDC
- 33342-313 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 5 mg/1
- Imprint
- Unknown — pending review
- Color
- Unknown — pending review
- Shape
- Unknown — pending review
- Form
- TABLET
- Labeler
- Bryant Ranch Prepack
- NDC
- 71335-1732 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 28 mg/1
- Imprint
- AN 785
- Color
- green
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Amneal Pharmaceuticals LLC
- NDC
- 65162-785 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 7 mg/1
- Imprint
- AN 782
- Color
- yellow
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Amneal Pharmaceuticals LLC
- NDC
- 65162-782 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 14 mg/1
- Imprint
- AN 783
- Color
- green
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Amneal Pharmaceuticals LLC
- NDC
- 65162-783 ↗ · 2026-06-18
- Strength
- MEMANTINE HYDROCHLORIDE 21 mg/1
- Imprint
- AN 784
- Color
- green
- Shape
- CAPSULE
- Form
- CAPSULE, EXTENDED RELEASE
- Labeler
- Amneal Pharmaceuticals LLC
- NDC
- 65162-784 ↗ · 2026-06-18
Dosage
Pending medical reviewer
